Investor Overview
Corporate Profile
Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's product candidate, peginesatide (formerly known as Hematide™), has been investigated in Phase 3 clinical trials for the potential treatment of anemia associated with chronic renal failure.
Events & Webcasts
|
Jan 10, 2012
|
Recent Press Releases
Transfer Agent
Computershare Trust Company, Inc.
350 Indiana Street, Suite 800, Golden, Colorado 80401
(800) 962-4284